By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Biogen, Inc. 

14 Cambridge Center

Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-679-2000 Fax:



Company News
Nine Boston Biotechs That Are Actually Profitable 7/22/2015 6:37:00 AM
Biogen, Inc. Second Quarter 2014 Revenues Increase 40% To $2.4 Billion; Company Raises Financial Guidance For The Year 7/23/2014 8:42:08 AM
FDA Approves Biogen, Inc.'s Hemophilia A Drug Eloctate 6/6/2014 4:18:09 PM
Biogen, Inc. Profit Rises As New Multiple Sclerosis Drug Shines 1/29/2014 7:51:00 AM
Social Media Suggests an MS Dogfight Between Biogen, Inc. and Novartis AG (NVS) 5/24/2013 8:28:41 AM
Biogen, Inc. Release: FAMPYRA(TM), the First Oral Treatment for the Improvement of Walking in MS, is Now Available in Canada 4/11/2012 9:46:17 AM
Biogen, Inc. Takes Option to MAKScientific, LLC MS Program 3/15/2012 8:45:06 AM
Biogen, Inc. Appoints Kenneth DiPietro Executive Vice President, Human Resources 1/30/2012 6:20:18 AM
Biogen, Inc., and Elan Corporation PLC (ELN) Release: ASCEND Study to Evaluate the Effectiveness of TYSABRI┬« (natalizumab) as a Treatment for Secondary-Progressive Multiple Sclerosis 1/26/2012 7:16:11 AM
Biogen, Inc. to Report Fourth Quarter & Year End 2011 Financial Results on January 31, 2012 1/17/2012 5:52:36 AM